ARMC1 Inhibitors are a specialized class of chemical compounds designed to target and inhibit the activity of the ARMC1 protein, a member of the armadillo repeat-containing (ARMC) family. Proteins in this family are characterized by the presence of armadillo (ARM) repeats, which are motifs involved in mediating protein-protein interactions. ARMC1 is implicated in various cellular processes, including the regulation of cytoskeletal organization, cell signaling, and the maintenance of cellular architecture. ARMC1 Inhibitors function by binding to specific regions of the ARMC1 protein, such as its ARM repeat domains or other functional motifs critical for its interactions with other proteins. This binding can disrupt ARMC1's ability to engage in protein-protein interactions or interfere with its role in cellular scaffolding, thereby altering the pathways and processes in which ARMC1 is involved.
The design and effectiveness of ARMC1 Inhibitors rely heavily on their chemical properties and molecular structure. These inhibitors are typically engineered to interact precisely with the ARM repeat domains of ARMC1, where they can compete with natural binding partners or directly block the interaction sites. The molecular design may include hydrophobic regions that fit into non-polar pockets within the ARM domains, as well as polar or charged groups that establish hydrogen bonds or electrostatic interactions with key amino acids critical for the stability and function of ARMC1. Additionally, some inhibitors may be designed to target other regions of ARMC1 that are essential for its localization or stability within the cell, further enhancing their inhibitory effect. The solubility, stability, and bioavailability of these inhibitors are optimized to ensure they can effectively reach and bind to ARMC1 in its native cellular environment. The kinetics of binding, including how quickly and tightly the inhibitor associates with and dissociates from ARMC1, are crucial factors that influence the overall potency and duration of inhibition. By studying the interactions between ARMC1 Inhibitors and their target protein, researchers can gain deeper insights into the molecular mechanisms governing cytoskeletal organization and protein interaction networks, as well as the broader implications of modulating ARMC1 activity within various cellular contexts. Understanding these interactions is essential for elucidating how ARMC1 contributes to maintaining cellular structure and function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A inhibits histone deacetylases, leading to hyperacetylation of histones and potentially repressing ARMC1 gene transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine incorporates into DNA and RNA, causing hypomethylation of DNA which may inhibit ARMC1 gene expression. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D intercalates into DNA, preventing RNA polymerase from transcribing DNA, which could inhibit ARMC1 expression. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin binds to RNA polymerase II, inhibiting mRNA synthesis and potentially decreasing ARMC1 expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Mithramycin A binds to GC-rich sequences in DNA, potentially blocking ARMC1 gene transcription. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine intercalates into DNA and RNA, which can disrupt transcription and potentially lower ARMC1 levels. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide has been shown to inhibit transcriptional activity, possibly affecting ARMC1 mRNA synthesis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Sirolimus binds to mTOR, possibly causing downregulation of ARMC1 through complex transcriptional networks. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin inhibits DNA topoisomerase I, leading to reduced transcription and potentially lower ARMC1 expression. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $42.00 $185.00 $310.00 $650.00 | 6 | |
DRB inhibits RNA Polymerase II, potentially downregulating ARMC1 mRNA synthesis. | ||||||